CSIMarket


Terms Beginning with S
                       
                       
 S&P 500 Index   Securitization   Service Fees  
 S&P GSCI Commodity Index   Securitization Income   Services  
 S-Curve Method   Seed Capital   Servicing Carrier  
 Sales per Employee   Segment   Severity Rate  
 Salt   Seismic   Shaft  
 Salvage   Seismic Zone   Shares Outstanding, Outstanding Shares  
 Sampling   Self Insured Retentions   Shelf Registration Statement  
 Scrap Iron and Steel   Semiconductors   Shipments Manufacturing  
 Second Injury Fund   Sensitivity   Short Selling  
 Second-line   Seq. Sequential QQ MM   Short Ton  
                 
                  next arrow
 
 
       
       
 

Special Protocol Assessment or SPA

Health Care Term


Special Protocol Assessment (SPA) is a process used by the U.S. Food and Drug Administration (FDA) to evaluate the design and objectives of clinical trials for new drugs or biologics. It is a formal agreement between the FDA and the sponsor of a clinical trial, in which the FDA reviews and approves the study design, patient population, endpoints, and statistical analyses before the trial begins.

The purpose of SPA is to ensure that the proposed clinical trial is scientifically sound, adequately designed, and capable of providing sufficient data to support a regulatory decision on the safety and effectiveness of the drug or biologic. It aims to prevent delays and uncertainties in the drug development process by establishing clear expectations and reducing the risk of major disagreements between the sponsor and the FDA about the trial design.

SPA is particularly useful for drugs that address serious or life-threatening conditions, have no available treatments, or represent a significant improvement over existing therapies. It can also be helpful for drugs that have complex or innovative designs, such as adaptive trials, or for which there is a high degree of uncertainty about the optimal dose, patient population, or primary endpoint.

In the healthcare industry, SPA is an important tool for drug development companies, as it gives them more certainty and predictability in the regulatory process and may enhance their ability to secure funding from investors or partners. It also benefits patients and healthcare providers, as it facilitates the timely development and approval of safe and effective treatments for unmet medical needs.


   
     

Special Protocol Assessment or SPA

Health Care Term


Special Protocol Assessment (SPA) is a process used by the U.S. Food and Drug Administration (FDA) to evaluate the design and objectives of clinical trials for new drugs or biologics. It is a formal agreement between the FDA and the sponsor of a clinical trial, in which the FDA reviews and approves the study design, patient population, endpoints, and statistical analyses before the trial begins.

The purpose of SPA is to ensure that the proposed clinical trial is scientifically sound, adequately designed, and capable of providing sufficient data to support a regulatory decision on the safety and effectiveness of the drug or biologic. It aims to prevent delays and uncertainties in the drug development process by establishing clear expectations and reducing the risk of major disagreements between the sponsor and the FDA about the trial design.

SPA is particularly useful for drugs that address serious or life-threatening conditions, have no available treatments, or represent a significant improvement over existing therapies. It can also be helpful for drugs that have complex or innovative designs, such as adaptive trials, or for which there is a high degree of uncertainty about the optimal dose, patient population, or primary endpoint.

In the healthcare industry, SPA is an important tool for drug development companies, as it gives them more certainty and predictability in the regulatory process and may enhance their ability to secure funding from investors or partners. It also benefits patients and healthcare providers, as it facilitates the timely development and approval of safe and effective treatments for unmet medical needs.


Related Health Care Terms
                     
                     
 Adenocarcinoma   Analogues   Arrhythmia  
 Adenosine   ANDA Abbreviated New Drug Application   Arteriosclerosis  
 Adult Stem Cell   Angina   Atherosclerosis  
 Adverse Event   Angiogenesis   Autologous  
 Agonist   Angioplasty   Balloon Angioplasty  
 AIDS   Antagonist   Bioavailability  
 Alkylation Agent   Anti Hypertensive   Biologic Products  
 Allogeneic   Antibody   Biomarker  
 Amino Acid   Antigen   Bradycardia  
 Analgesic   API   Cancer  
               
                  next arrow
 
   


Help

About us

Advertise